AAAAAA

   
Results: 1-10 |
Results: 10
PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS
Authors: ABIGERGES D ARMAND JP CHABOT GG BRUNO R BISSERY MC BAYSSAS M KLINKALAKL M CLAVEL M CATIMEL G
Citation: D. Abigerges et al., PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS, Anti-cancer drugs, 7(2), 1996, pp. 166-174
DOCETAXEL - AN ACTIVE NEW DRUG FOR TREATMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER
Authors: PICCART MJ GORE M HUININK WTB VANOOSTEROM A VERWEIJ J WANDERS J FRANKLIN H BAYSSAS M KAYE S
Citation: Mj. Piccart et al., DOCETAXEL - AN ACTIVE NEW DRUG FOR TREATMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER, Journal of the National Cancer Institute, 87(9), 1995, pp. 676-681
DOCETAXEL IS A MAJOR CYTOTOXIC DRUG FOR THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE CLINICAL SCREENING COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
Authors: CHEVALLIER B FUMOLEAU P KERBRAT P DIERAS V ROCHE H KRAKOWSKI I AZLI N BAYSSAS M LENTZ MA VANGLABBEKE M
Citation: B. Chevallier et al., DOCETAXEL IS A MAJOR CYTOTOXIC DRUG FOR THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE CLINICAL SCREENING COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER, Journal of clinical oncology, 13(2), 1995, pp. 314-322
CURRENT STATUS OF TAXOTERE(R) (DOCETAXEL) AS A NEW TREATMENT IN BREAST-CANCER
Authors: FUMOLEAU P CHEVALLIER B KERBRAT P DIERAS V AZLI N BAYSSAS M VANGLABBEKE M
Citation: P. Fumoleau et al., CURRENT STATUS OF TAXOTERE(R) (DOCETAXEL) AS A NEW TREATMENT IN BREAST-CANCER, Breast cancer research and treatment, 33(1), 1995, pp. 39-46
IN-VIVO STIMULATION OF NEUTROPHIL FUNCTION BY LENOGRASTIM (GLYCOSYLATED RHUG-CSF) IN ONCOHEMATOLOGIC PATIENTS - RESULTS OF A PHASE-I TRIAL
Authors: FOSSAT C STOPPA AM SAINTY D BLAISE D VIENS P BAYSSAS M YVER A JUHANVAGUE I MARANINCHI D
Citation: C. Fossat et al., IN-VIVO STIMULATION OF NEUTROPHIL FUNCTION BY LENOGRASTIM (GLYCOSYLATED RHUG-CSF) IN ONCOHEMATOLOGIC PATIENTS - RESULTS OF A PHASE-I TRIAL, Stem cells, 12(3), 1994, pp. 322-328
DOCETAXEL (TAXOTERE) IN ADVANCED RENAL-CELL CANCER - A PHASE-II TRIALOF THE EORTC EARLY CLINICAL-TRIALS GROUP
Authors: BRUNTSCH U HEINRICH B KAYE SB DEMULDER PHM VANOOSTEROM A PARIDAENS R VERMORKEN JB WANDERS J FRANKLIN H BAYSSAS M VERWEIJ J
Citation: U. Bruntsch et al., DOCETAXEL (TAXOTERE) IN ADVANCED RENAL-CELL CANCER - A PHASE-II TRIALOF THE EORTC EARLY CLINICAL-TRIALS GROUP, European journal of cancer, 30A(8), 1994, pp. 1064-1067
A PHASE-II TRIAL WITH DOCETAXEL (TAXOTERE(TM)) IN 2ND LINE TREATMENT WITH CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP
Authors: HUININK WWT PROVE AM PICCART M STEWARD W TURSZ T WANDERS J FRANKLIN H CLAVEL M VERWEIJ J ALAKL M BAYSSAS M KAYE SB
Citation: Wwt. Huinink et al., A PHASE-II TRIAL WITH DOCETAXEL (TAXOTERE(TM)) IN 2ND LINE TREATMENT WITH CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP, Annals of oncology, 5(6), 1994, pp. 527-532
PHASE-I STUDY OF DOCETAXEL ADMINISTERED AS A 1-HOUR INTRAVENOUS-INFUSION ON A WEEKLY BASIS
Authors: TOMIAK E PICCART MJ KERGER J LIPS S AWADA A DEVALERIOLA D RAVOET C LOSSIGNOL D SCULIER JP AUZANNET V LEBAIL N BAYSSAS M KLASTERSKY J
Citation: E. Tomiak et al., PHASE-I STUDY OF DOCETAXEL ADMINISTERED AS A 1-HOUR INTRAVENOUS-INFUSION ON A WEEKLY BASIS, Journal of clinical oncology, 12(7), 1994, pp. 1458-1467
DESIGN AND PROSPECTIVE IMPLEMENTATION OF POPULATION PHARMACOKINETIC STUDIES DURING THE DEVELOPMENT OF DOCETAXEL (D) (RP-56976) - A NEW ANTICANCER DRUG
Authors: BRUNO R DORR MB MONTAY G FRYDMAN A THIS F FUMOLEAU P KAY S KAVANAGH GH BURRIS HA RIGAS JR BAYSSAS M
Citation: R. Bruno et al., DESIGN AND PROSPECTIVE IMPLEMENTATION OF POPULATION PHARMACOKINETIC STUDIES DURING THE DEVELOPMENT OF DOCETAXEL (D) (RP-56976) - A NEW ANTICANCER DRUG, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 161-161
PHASE-I CLINICAL-TRIAL OF TAXOTERE ADMINISTERED AS EITHER A 2-HOUR OR6-HOUR INTRAVENOUS-INFUSION
Authors: BURRIS H IRVIN R KUHN J KALTER S SMITH L SHAFFER D FIELDS S WEISS G ECKARDT J RODRIGUEZ G RINALDI D WALL J COOK G SMITH S VREELAND F BAYSSAS M LEBAIL N VONHOFF D
Citation: H. Burris et al., PHASE-I CLINICAL-TRIAL OF TAXOTERE ADMINISTERED AS EITHER A 2-HOUR OR6-HOUR INTRAVENOUS-INFUSION, Journal of clinical oncology, 11(5), 1993, pp. 950-958
Risultati: 1-10 |